406722-15-4Relevant academic research and scientific papers
Discovery of a fluoroindolo[2,3-a]carbazole clinical candidate with broad spectrum antitumor activity in preclinical tumor models superior to the marketed oncology drug, CPT-11
Saulnier, Mark G.,Balasubramanian, Balu N.,Long, Byron H.,Frennesson, David B.,Ruediger, Edward,Zimmermann, Kurt,Eummer, Jeffrey T.,St. Laurent, Denis R.,Stoffan, Karen M.,Naidu, B. Narasimhulu,Mahler, Mikael,Beaulieu, Francis,Bachand, Carol,Lee, Frank Y.,Fairchild, Craig R.,Stadnick, Linda K.,Rose, William C.,Solomon, Carola,Wong, Henry,Martel, Alain,Wright, John J.,Kramer, Robert,Langley, David R.,Vyas, Dolatrai M.
, p. 2258 - 2261 (2005)
A series of fluoroglycosylated fluoroindolocarbazoles was examined with respect to their topoisomerase I activity, cytotoxicity, and selectivity. The lead clinical candidate from this series, BMS-250749, displays broad spectrum antitumor activity superior
